The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cyclooxygenase-1 and -2–Dependent Prostacyclin Formation in Patients With Atherosclerosis
Abstract
Background—The formation of prostacyclin (PGI 2), thromboxane (TX) A 2, and isoprostanes is markedly enhanced in atherosclerosis. We examined the relative contribution of cyclooxygenase (COX)-1 and -2 to the generation of these eicosanoids in patients with atherosclerosis. Methods and Results—The study population consisted of 42 patients with atherosclerosis who were undergoing surgical revascularization. COX-2 mRNA was detected in areas of atherosclerosis but not in normal blood vessel walls, and there was evidence of COX-1 induction. The use of immunohistochemical studies localized the COX-2 to proliferating vascular smooth muscle cells and macrophages. Twenty-four patients who did not previously receive aspirin were randomized to receive either no treatment or nimesulide at 24 hours before surgery and then for 3 days. Eighteen patients who were receiving aspirin were continued on a protocol of either aspirin alone or a combination of aspirin and nimesulide. Urinary levels of 11-dehydro-TXB 2 and 2,3-dinor-6-keto-PGF 1α, metabolites of TXA 2 and PGI 2, respectively, were elevated in patients with atherosclerosis compared with normal subjects (3211±533 versus 679±63 pg/mg creatinine,P<0.001; 594±156 versus 130±22 pg/mg creatinine,P<0.05, respectively), as was the level of the isoprostane 8-iso-PGF 2α. Nimesulide reduced 2,3-dinor-6-keto-PGF 1α excretion by 46±5% (378.3±103 to 167±37 pg/mg creatinine,P<0.01) preoperatively and blunted the increase after surgery. Nimesulide had no significant effect on 11-dehydro-TXB 2 before (2678±694 to 2110±282 pg/mg creatinine) or after surgery. The levels of both products were lower in patients who were taking aspirin, and no further reduction was seen with the addition of nimesulide. None of the treatments influenced urinary 8-iso-PGF 2α excretion. Conclusions—Both COX-1 and -2 are expressed and contribute to the increase in PGI 2 in patients with atherosclerosis, whereas TXA 2 is generated by COX-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.
Hamberg, M., Svensson, J., & Samuelsson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.2994 · Cited by 3,045
Galis, Z. S., Sukhova, G. K., Lark, M. W., & Libby, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117619 · Cited by 2,539
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
Low Density Lipoprotein Oxidation and Its Pathobiological Significance
Steinberg, D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.20963 · Cited by 1,642
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
Tsujii, M., Kawano, S., & DuBois, R. N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3336 · Cited by 1,398
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Meade, E. A., Smith, W. L., & DeWitt, D. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53294-4 · Cited by 1,256
Platelet Activation in Unstable Coronary Disease
Fitzgerald, D. J., Roy, L., Catella, F., & FitzGerald, G. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610163151602 · Cited by 1,141
Self-citationBunting, S., Moncada, S., Vane, J. R., & Gryglewski, R. (1976) · Prostaglandins · doi:10.1016/0090-6980(76)90125-8 · Cited by 950
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.
Fu, J. Y., Masferrer, J. L., Seibert, K., Raz, A., & Needleman, P. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44821-6 · Cited by 944
Pharmacological analysis of cyclooxygenase-1 in inflammation
Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., & Isakson, P. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13313 · Cited by 807
Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., et al. (1997) · Nature · doi:10.1038/41780 · Cited by 773
Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., & Prescott, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52976-8 · Cited by 708
Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues
O'Neill, G. P., & Ford-Hutchinson, A. W. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80263-t · Cited by 707
Gown, A. M., Tsukada, T., & Ross, R. (1986) · PubMed · Cited by 676
Schmedtje, J. F., Ji, Y.-S., Liu, W.-L., DuBois, R. N., & Runge, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.601 · Cited by 668
FitzGerald, G. A., Oates, J. A., Hawiger, J., Maas, R. L., Roberts, L. J., Lawson, J. A., & Brash, A. R. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110814 · Cited by 665
Catella-Lawson, F., McAdam, B., Morrison, B. W., Kapoor, S., Kujubu, D., Antes, L., Lasseter, K. C., Quan, H., Gertz, B. J., & Fitzgerald, G. A. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38195-9 · Cited by 597
Taylor, D. W., Barnett, H. J., Haynes, R. B., Ferguson, G. G., Sackett, D. L., Thorpe, K. E., Simard, D., Silver, F. L., Hachinski, V., Clagett, G. P., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05388-x · Cited by 530 · cited 1×
“42 Moreover, a recent study that showed greater efficacy in stroke prevention with a lower dose of aspirin suggests a role for endogenous PGI 2.(43) Thus, the reduction in PGI2formation seen with a COX-2 inhibitor in the presence of normal TXA 2 formation may place patients at an increased risk of thrombosis.”
Takahashi, K., Nammour, T. M., Fukunaga, M., Ebert, J., Morrow, J. D., Roberts, L. J., Hoover, R. L., & Badr, K. F. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115826 · Cited by 511
Praticò, D., Tangirala, R. K., Rader, D. J., Rokach, J., & FitzGerald, G. A. (1998) · Nature Medicine · doi:10.1038/2685 · Cited by 501
Mach, F., Schönbeck, U., Bonnefoy, J.-Y., Pober, J. S., & Libby, P. (1997) · Circulation · doi:10.1161/01.cir.96.2.396 · Cited by 493
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.
FitzGerald, G. A., Pedersen, A. K., & Patrono, C. (1983) · Circulation · doi:10.1161/01.cir.67.6.1174 · Cited by 466
Fitzgerald, D. J., Catella, F., Roy, L., & FitzGerald, G. A. (1988) · Circulation · doi:10.1161/01.cir.77.1.142 · Cited by 433
Self-citationAugmented Expression of Cyclooxygenase-2 in Human Atherosclerotic Lesions
Schönbeck, U., Sukhova, G. K., Graber, P., Coulter, S., & Libby, P. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65230-3 · Cited by 379
Adderley, S. R., & Fitzgerald, D. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.5038 · Cited by 371
Self-citationSuppression of Thromboxane A2but Not of Systemic Prostacyclin by Controlled-Release Aspirin
Clarke, R. J., Mayo, G., Price, P., & FitzGerald, G. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110173251605 · Cited by 346
Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry.
Ross, R. (1993) · PubMed · Cited by 345
Localization of distinct F2-isoprostanes in human atherosclerotic lesions.
Praticò, D., Iuliano, L., Mauriello, A., Spagnoli, L., Lawson, J. A., Rokach, J., Maclouf, J., Violi, F., & FitzGerald, G. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119735 · Cited by 344
Wallace, J. L., Bak, A., McKnight, W., Asfaha, S., Sharkey, K. A., & MacNaughton, W. K. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70370-1 · Cited by 336
Baker, C. S. R., Hall, R. J. C., Evans, T. J., Pomerance, A., Maclouf, J., Creminon, C., Yacoub, M. H., & Polak, J. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.646 · Cited by 296
Cylooxygenase-dependent Formation of the Isoprostane, 8-Epi Prostaglandin F2α
Pratico, D., Lawson, J. A., & FitzGerald, G. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.17.9800 · Cited by 264
Xie, W., & Herschman, H. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31742 · Cited by 240
Morrow, J. D., Minton, T. A., & Roberts, L. J. (1992) · Prostaglandins · doi:10.1016/0090-6980(92)90077-7 · Cited by 215
Generation of 8-Epiprostaglandin F by Human Monocytes
Praticó, D., & FitzGerald, G. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8919 · Cited by 187
Cipollone, F., Patrignani, P., Greco, A., Panara, M. R., Padovano, R., Cuccurullo, F., Patrono, C., Rebuzzi, A. G., Liuzzo, G., Quaranta, G., et al. (1997) · Circulation · doi:10.1161/01.cir.96.4.1109 · Cited by 182
Selective Cyclooxygenase-2 Inhibition by Nimesulide in Man
Cullen, L., Kelly, L. P., Connor, S. O., & Fitzgerald, D. J. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37830-9 · Cited by 144
Self-citationPanara, M. R., Greco, A., Santini, G., Sciulli, M. G., Rotondo, M. T., Padovano, R., di Giamberardino, M., Cipollone, F., Cuccurullo, F., Patrono, C., et al. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15091.x · Cited by 83
Human globin gene analysis for a patient with beta-o/delta beta-thalassemia.
Ottolenghi, S., Lanyon, W. G., Williamson, R., Weatherall, D. J., Clegg, J. B., & Pitcher, C. S. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.6.2294 · Cited by 69
Cyclooxygenase‐Dependent Formation of the Isoprostane 8‐EPI Prostaglandin F2αa
Praticò, D., Lawson, J. A., & FitzGerald, G. A. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb52730.x · Cited by 66
The in vivo assessment of nimesulide cyclooxygenase-2 selectivity
Shah, A. (1999) · British journal of rheumatology · doi:10.1093/rheumatology/38.suppl_1.19 · Cited by 62
Sattar, A. A., Haot, J., Schulman, C. C., & Wespes, E. (1996) · British Journal of Urology · doi:10.1046/j.1464-410x.1996.83018.x · Cited by 19
Regan, C. L., McAdam, B. F., McParland, P., Boylan, P. C., FitzGerald, G. A., & Fitzgerald, D. J. (1998) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1998.tb10203.x · Cited by 15
Self-citation
Cited by
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Eikelboom, J. W., Hirsh, J., Weitz, J. I., Johnston, M., Yi, Q., & Yusuf, S. (2002) · Circulation · doi:10.1161/01.cir.0000013777.21160.07 · Cited by 1,053
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Metadata
- Authors
- Belton, O., Byrne, D., Kearney, D., Leahy, A., & Fitzgerald, D. J.
- Venue
- Circulation
- Published
- 2000-08-22
- Volume
- 102
- Issue
- 8
- Pages
- 840-845
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2053230224
- Cited by
- 377
- References
- 45
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.